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Mycobacterium tuberculosis whole 
genome sequencing provides 
insights into the Manila strain and 
drug-resistance mutations in the 
philippines
Jody e. phelan  1, Dodge R. Lim  2,3, satoshi Mitarai4, paola Florez de sessions5, 
Ma. Angelica A. tujan  6, Lorenzo t. Reyes2,3, Inez Andrea p. Medado6, Alma G. palparan2,3, 
Ahmad Nazri Mohamed Naim5, song Jie5, edelwisa segubre-Mercado6, Beatriz simoes1, 
susana Campino1, Julius C. Hafalla1, Yoshiro Murase4, Yuta Morishige  4, Martin L. Hibberd1, 
seiya Kato4, Ma. Cecilia G. Ama2,3 & taane G. Clark  1,7
the philippines has a high incidence of tuberculosis disease (tB), with an increasing prevalence of 
multidrug-resistant Mycobacterium tuberculosis (MDR-TB) strains making its control difficult. Although 
the M. tuberculosis “Manila” ancient lineage 1 strain-type is thought to be prevalent in the country, 
with evidence of export to others, little is known about the genetic diversity of circulating strains. By 
whole genome sequencing (WGS) 178 isolates from the Philippines National Drug Resistance Survey, 
we found the majority (143/178; 80.3%) belonged to the lineage 1 Manila clade, with the minority 
belonging to lineages 4 (European-American; n = 33) and 2 (East Asian; n = 2). A high proportion were 
found to be multidrug-resistant (34/178; 19.1%), established through highly concordant laboratory 
drug susceptibility testing and in silico prediction methods. some MDR-tB isolates had near identical 
genomic variation, providing potential evidence of transmission. By placing the philippine isolates 
within a phylogeny of global M. tuberculosis (n > 17,000), we established that they are genetically 
similar to those observed outside the country, including a clade of Manila-like strain-types in thailand. 
An analysis of the phylogeny revealed a set of ~200 SNPs that are specific for the Manila strain-type, 
and a subset can be used within a molecular barcode. sixty-eight mutations known to be associated 
with 10 anti-TB drug resistance were identified in the Philippine strains, and all have been observed in 
other populations. Whilst nine putative streptomycin resistance conferring markers in gid (8) and rrs (1) 
genes appear to be novel and with functional consequences. overall, this study provides an important 
baseline characterisation of M. tuberculosis genetic diversity for the Philippines, and will fill a gap in 
global datasets and aid the development of a nation-wide database for epidemiological studies and 
clinical decision making. Further, by establishing a molecular barcode for detecting Manila strains it will 
assist with the design of diagnostic tools for disease control activities.
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Tuberculosis disease (TB) is a chronic respiratory infection, caused by Mycobacterium tuberculosis. The 
Philippines is a high-burden country for TB, with over 300,000 cases and 25,000 deaths in 2017 alone1. However, 
recent findings suggest that over a million Filipinos are actively infected with the disease, placing the Philippines 
burden second to China1. Furthermore, the country has an increasing HIV prevalence and a high burden for 
multidrug-resistance (MDR-TB, resistance to isoniazid and rifampicin (RIF) treatments) that pose serious chal-
lenges for effective control1. The Philippines has adopted the World Health Organisation (WHO) TB - “Directly 
Observed Treatment, Short Course” (TB-DOTS) control strategy. It has been recognised that there is an urgent 
need to detect and treat more cases through an expansion of GeneXpert (Cepheid, Sunnyvale, CA) facilities for 
better access and for use as a primary diagnostic tool1. In particular, there is a gap among those expected to have 
MDR-TB (2% new, 21% retreatment cases) and those detected and subsequently put on treatment. Furthermore, 
treatment outcomes among those treated show poor success rates, thereby putting the country at risk to the fur-
ther spread of MDR-TB and potentially extensively drug-resistant strains.
Despite TB being a serious problem in the Philippines, genomic data for local M. tuberculosis strains is lack-
ing. Previous studies have identified ‘ancient’ (lineage 1) and ‘modern’ lineages (2 and 4) as being present in the 
population2 with the members of the EA12-Manila clade known to be highly associated with the Filipino popu-
lation3,4. More isolates are needed to accurately infer the phylogeographic distribution of M. tuberculosis strains 
in the country, and take advantage of new genomic tools that allow for whole genome sequencing (WGS). WGS 
data can be used to profile the M. tuberculosis for drug resistance5,6, characterise the ancient and modern lineages 
and different virulence strain-types7, and establish who may have transmitted to whom and thus allow targeted 
resources to hotspot areas to reduce transmission8; all made possible through advances in health informatics5. 
Further, WGS opportunities are set to revolutionise the diagnosis and clinical patient management of TB. For 
example, Public Health England (UK) now uses pathogen genetic characterisation as a clinical standard of care 
in TB management, and an increasing number of countries worldwide are seeking to adopt this as part of clinical 
care. However, to be effective these approaches need to be applied in countries with high TB burdens and coordi-
nated with established control programmes.
In the Philippines, a nationwide drug resistance survey (DRS) occurs quinquennially (years 2007, 2012, 2017) 
and there is active surveillance of MDR-TB, including monitoring of fluoroquinolone and second line injectables 
resistance among TB patients, which involves  the sequencing of drug resistance loci. This involves characteris-
ing single nucleotide polymorphisms (SNPs) and indel markers of drug resistance, especially in genes coding 
for drug-targets or -converting enzymes (e.g. katG, inhA, rpoB, pncA, embB, rrs, gyrA, gyrB genes). Limited sets 
of high frequency markers have been included in diagnostic tools (e.g. Xpert MTB/RIF and line probe assays 
for MDR-TB) for identification in M. tuberculosis DNA (approximate genome size 4.4 Mb). However, these 
approaches use less than 1% of the genome, and WGS approaches that identify SNPs and other variation provide 
far greater resolution for profiling M. tuberculosis for drug resistance, strain-types and detecting outbreaks, but 
also inform new mutations and mechanisms through genome-wide analyses6,9.
To date, there have been few WGS studies in the Philippines, and here we present the results of sequencing 
178 isolates recently collected in the 2012 DRS. We explore the genomic diversity of predominant Manila strain 
and develop a molecular barcode for surveillance applications. We show that the strain-types and majority of 
drug resistance mutations identified are similar to those found in global populations, making the use of existing 
mutation databases robust to detect resistance.
Results and Discussion
Clinical isolates and phylogeny. A total of 178 M. tuberculosis isolates were sourced from the nationwide 
“cluster-based”, cross-sectionally designed TB DRS (2012), which was implemented with cross re-checking stand-
ards according to the WHO guidelines. The isolates were randomly selected to represent the different geographic 
regions (“clusters”) in the Philippines. (Fig. 1A; Table 1). The isolates underwent culture, drug susceptibility test-
ing (DST) across 8 drugs (Table 1), and WGS. The DST results revealed 97 (54.5%) isolates as pan-susceptible, 
34 (19.1%) MDR-TB (resistance to both rifampicin and isoniazid) and 47 (26.4%) non-MDR-TB drug-resistant 
(resistance to at least one drug but not to both rifampicin and isoniazid). No XDR-TB isolates were found, con-
firming earlier reports of low levels of fluoroquinolone resistance10. Mapping of the raw sequence data led to high 
average genome-wide coverage across the samples (median: 100.5-fold; range: 52- to 2,263-fold). Across the clin-
ical isolates, 17,522 unique SNPs were identified, and a high proportion (50%) were observed in single isolates. 
Isolates were classified into lineages 1 (n = 143; 80.3%), 4 (n = 33; 18.5%) and 2 (n = 2; 1.1%), and as expected 
these form clusters on the phylogeny constructed using all SNP sites (Fig. 1B). By inferring spoligotypes from 
the WGS data, the EA12-Manila spoligotype (lineage 1.2.1)3 was found to have the highest frequency (n = 143, 
80.3%) among lineage 1 strains (Table 1).
evidence of transmission. Potential transmission clusters were found by calculating the pairwise SNP dis-
tance between isolates and using an established difference cut-off of 10 SNPs or less8. Fifteen clusters were found, 
with a  maximum size of three isolates. Of these clusters, nine contained MDR-TB strains, ten belonged to lineage 
1, and five to lineage 4 (Supplementary Fig. 2). In order to establish whether particular strains are circulating locally 
or nation-wide, the phylogeographical distribution of the 178 strains was analysed (Supplementary Fig. 3A). There 
was no association of island group (Luzon, Mindanao and Visayas) with phylogenetic placement (Slatkin-Maddison 
P = 0.87). Using the closest neighbour for each strain, a weak correlation between genetic distance (SNP differences) 
and geographic distance was observed (Spearmans correlation = 0.36) (Supplementary Fig. 3B).
the Manila strain. This collection represents the largest number of Manila strains sequenced from the 
Philippines with WGS (n = 143). To determine if the Philippine strains formed their own monophyletic clade 
compared to other strains, we reconstructed a phylogenetic tree that also included lineage 1.2.1 strains with 
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publicly available sequences (n = 408). The Philippine isolates did not form a monophyletic group within the 
tree and were interleaved with strains from Thailand, UK, Saudi Arabia, India, and Vietnam among others 
(Supplementary Fig. 4). Most of these were sporadically scattered throughout the tree, however a large monophy-
letic clade with 114 isolates formed comprising of predominantly Thai strains. To determine the geographic origin 
of the most recent common ancestor (MRCA) of this clade, we performed ancestral state reconstruction using 
stochastic character mapping. The most likely location of the Thai clade MRCA was estimated to be from the 
Philippines (posterior probability = 0.79). Based on this, a likely scenario is that lineage 1.2.1 strains in Thailand 
were imported from the Philippines, after which they diversified. In-silico spoligotyping of this clade revealed a 
very different strain-type from the Manila spoligotype, with the loss of spacers 7–18 and 21–24, corresponding to 
the previously described EAI2-Nonthaburi spoligotype11. A comparison of allele frequency differences between 
the Manila (N = 408) and non-Manila strains in neighbouring clades (N = 1,636) revealed 197 SNPs which were 
specific to the Manila clade. Of these, 180 were found in coding regions and 115 led to amino acid changes, 
including one premature stop codon in whiB5, which has been described before12 (Supplementary Data 1).
Mutations underlying drug-resistance. Resistance profiles were predicted in silico using an estab-
lished library of mutations (https://github.com/jodyphelan/tbdb), and were compared to DST results. Assuming 
DST as the gold standard, the sensitivity and specificity was calculated for rifampicin, isoniazid, ethambutol 
and streptomycin, where all had at least 10 isolates with demonstrated phenotypic resistance. The sensitivity 
of prediction was high (>90%) across the drugs except streptomycin. The specificity was high (>95%) for all 
drugs (Supplementary Table 1). The relative low sensitivity of the streptomycin predictions was investigated and 
revealed nine novel polymorphisms in the gid (8 mutations) and rrs (1 mutation) genes in 12 false negative iso-
lates, which could potentially confer drug resistance. To investigate these mutations, we looked at their frequency 
in a large dataset of ~17,000 publicly available strains. Of the nine mutations, six were found in the global dataset 
and only one of these was found to be a lineage-specific marker (gid L16R) with the other five displaying charac-
teristics of convergent evolution. The functional consequences of the mutations in gid were investigated, and it 
was established that two (W45*, S181*) led to premature stop codons, two (CA49C, AC194A) led to frameshifts, 
and three (G71R, V77G and D85G) were within or close to the S-adenosyl-L-methionine (SAM)-binding motif. 
The SAM-binding motif is an important functional domain required by gid to methylate the G527 on the 530 
loop of 16S rRNA, which is thought to be the binding location of streptomycin13 (Supplementary Fig. 5). These 
mutations could represent resistance conferring mutations and should be investigated further. Overall, 68 known 
drug resistance-related mutations were found across the 178 samples, and they varied in frequency (range: 1 to 
63 isolates) (Table 2). Although no phenotypic resistance to fluoroquinolones was found, one isolate had the 
N499K mutation in the gyrB gene. This mutation has been reported to be rare in clinical strains14 and is associated 
with resistance to moxifloxacin but not to ofloxacin or levofloxacin15. Predicted resistance to (non-streptomycin) 
aminoglycosides was also rare with only a single isolate presenting a resistance conferring mutation in rrs 
(A1401G).
summary. WGS is being used as a tool for epidemiological investigations and to assist TB clinical and control 
program decision making. However, most clinical applications of WGS are taking place in developed countries. 
We present the first WGS data from the nation-wide TB drug resistance survey in the Philippines. Most isolates 
were from the EAI2-Manila clade, which would make this the largest WGS study of this spoligotype, but is also 
Figure 1. The 178 M. tuberculosis isolates: (A) Map of the Philippines annotated with the source and drug-
resistance of the isolates; (B) A phylogenetic tree constructed using 17,522 SNPs.
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indicative that this clade is common. For comparison, a recent report of WGS of 10 Philippines samples included 
7 EAI2-Manila, 1 Beijing and 2 Euro-American strains2. In our WGS data, there was high SNP variability between 
isolates in the EAI2-Manila clade, and we identified 197 SNPs specific to the EAI2-Manila clade which could form 
the basis of a SNP barcode. There was some evidence of near identical isolates, which is indicative of transmis-
sion events. This observation is surprising as the samples were chosen pseudo-randomly from a large collection, 
but it may be indicative of many large transmission chains in the population. Future large-scale sequencing of 
isolates across the surveys is required to understand transmission patterns and dynamics. There is no evidence 
of a correlation between genetic and geographic distance, but this may reflect the within-country movement and 
non-localised transmission of strains in the Philippines. Finally, we performed in-silico drug resistance profiling 
and compared this to phenotypic DST results. We found a number of different mutations conferring resistance 
to first-line anti-TB drugs, and report novel potential resistance conferring mutations, which can be investigated 
experimentally. Further, the mutations observed are similar to those reported in other drug resistant M. tuber-
culosis from the Philippines2 and globally. Overall, our work reveals the utility of WGS for the prediction of drug 
resistance in the Philippines setting. The whole genome data generated will serve as a reference for the surveil-
lance of TB in the Philippines and the wider region.
Materials and Methods
DNA extraction and sequencing. A total of 178 M. tuberculosis short-term cultured isolates from spu-
tum samples collected from the second national DRS on TB in the Philippines (2012) were pseudo-randomly 
selected for the study, where selection was informed by the WHO cross re-checking standard. This study was 
given authorization by the Institutional Review Board of the Research Institute for Tropical Medicine in the 
Philippines (ID No. RITM-IRB 2017-05). The clinical samples were complemented by two replicates of the 
H37Rv reference strain. Drug susceptibility testing was performed for rifampicin, isoniazid, ethambutol, strep-
tomycin, amikacin, kanamycin, capreomycin and levofloxacin at the  National Tuberculosis Research Laboratory 
(NTRL) (Supplementary Table 1). For the H37Rv and 14 clinical isolates, inactivation of culture isolates was 
performed in a BSL-3 facility at the NTRL,  and DNA extraction at the Molecular Biology Laboratory at the 
Research Institute for Tropical Medicine (RITM). Total genomic DNA was extracted using a phenol-chloroform 
extraction procedure. DNA pellets were washed with 70% ethanol and resuspended in 100ul Buffer EB (QIAGEN 
Inc., Germantown, MD, USA). DNA extract concentration and quality were measured using a Qubit fluorometer 
(Life Technologies Holdings Pte Ltd, Singapore) and were visualized on a 1% agarose gel. Library preparation 
of the DNA samples was performed using QIAseq FX DNA library kit, following the manufacturer’s protocol. 
Agilent High Sensitivity DNA Kit (QIAGEN Inc., Germantown, MD, USA) was used to check for correct DNA 
fragment size after adapter ligation. The concentration and size of each DNA library was measured using Agilent 
Technologies DNA 1000 assay kit on Agilent Technologies 2100 Bioanalyzer. The H37Rv prepared DNA libraries 
were sequenced using Illumina HiSeq. 4000 Next Generation Sequencer (2 × 151 base pair reads) at the Genome 
Institute Singapore. Similarly, for the other 164 clinical strains, DNA extraction and purification were performed 
in the BSL-3 laboratory in the Research Institute of Tuberculosis (RIT) using Isoplant II (WAKO chemicals, 
Characteristic N %
Location*
  Luzon 105 59.0
  Visayas 37 20.8
  Mindanao 36 20.2
Lineages
  1 143 80.3
  2 2 1.1
  4 33 18.5
Drug resistance**
 Rifampicin 38 24.7
  Isoniazid 64 46.0
  Ethambutol 10 6.5
  Streptomycin 25 16.3
  Amikacin 2 1.1
  Capreomycin 2 1.2
  Kanamycin 8 4.5
  Pan-susceptible 97 54.5
  MDR-TB 34 21.5
  XDR-TB 0 0
Table 1. Mycobacterium tuberculosis samples (N = 178). *Island of collection for sequenced isolates. **The 
number resistant to the drug and percentage of tested isolates resistant; the denominator is the number of 
isolates for each drug with successfully performed susceptibility tests. The exception to this is the proportion 
of pan-susceptible which was calculated using the total number of samples. MDR-TB = multi-drug resistant; 
XDR-TB = extensively-drug resistant; there was no levofloxacin drug resistance.
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Japan). The clinical strains were sequenced on the Illumina MiSeq platform (350 forward and 250 reverse pair 
ends) at the RIT. All raw sequencing data is available (Supplementary Data 2).
Bioinformatic analyses. Sequence reads were inspected using fastQC (www.bioinformatics.babraham.
ac.uk/projects/fastqc/) as a primary assessment of data quality. The reads were trimmed using trimmomatic16 
(v0.38) to remove low quality sequences, and then mapped against the H37Rv reference genome (AL123456) using 
BWA (v0.7.17)17. SNPs were called using the BCF/VCF tool suite (v1.8)18 in regions where at least 10 reads were pres-
ent. SNPs were removed from non-unique regions of the genome (e.g. ppe genes). SNPs were converted into a FASTA 
format alignment, which was used as input to RAxML (v8.0.0)19 to reconstruct the phylogeny. Drug resistance profiles 
and lineages were predicted in-silico using TBProfiler (v2.0). SpolPred (v1)20 was used to in-silico predict spoligotypes. 
As expected the resolution from using spoligotypes alone did not have the power to differentiate distinct WGS-based 
clusters found on the phylogenetic tree (Supplementary Fig. 1). The Philippine isolates were compared to others in 
a global set6 with the same lineage (see Supplementary Data 3) and FST values were calculated for each SNP using 
vcftools (–weir-fst-pop) to identify Manila-strain specific markers. A Slatkin-Maddison test was applied to assess a 
geographic-phylogenetic association and was performed in R using the prmac/slatkin.maddison library.
Data Availability
Previously published and newly generated data can be found on the ENA using the Run accession codes in Sup-
plementary Data 2. The newly generated data can be found under the ENA study accession number ERP110368.
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